Here's some of what is coming soon to NeurologyLive® this week.
|Videos|October 21, 2021
Evolving Fellowship Training in Multiple Sclerosis
Ahmed Obeidat, MD, PhD; Jeffrey Cohen, MD; and Erin Longbrake, MD, PhD discuss the evolution of fellowship training for multiple sclerosis specialists.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Jeffrey Cohen, MD
Director, Mellen Center for Multiple Sclerosis Treatment and Research; Director, Experimental Therapeutics Program, Cleveland Clinic - Erin Longbrake, MD, PhD
Assistant Professor of Neurology; Director, Fellowship Program, Multiple Sclerosis & Other Inflammatory Brain Disease, Yale School of Medicine
Key Learning Objectives
- Fellowship training paths in multiple sclerosis
- Subspecialty certification training in multiple sclerosis
- Practical advice for the clinical care of multiple sclerosis
- The future of clinician training for multiple sclerosis care
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.
Here's some of what is coming soon to NeurologyLive® this week.
A new case report underscored the need to consider CNS lymphoproliferative disease when patients on chronic immunosuppression for neuromyelitis optica spectrum disorder develop unexplained neurologic decline.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 11, 2026.
The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
Gefurulimab Recommended for EU Approval in Generalized Myasthenia Gravis
3
Episode 175: Advancing the Ways of Treating Cluster Headache
4
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
5